Against the background of an increasingly aging global population, the incidence of thrombotic and hemostatic diseases, including cardiovascular diseases, remains high.

Stay up-to-date with the latest happenings in the rapidly evolving field of In Vitro Diagnostics (IVD) in China.

BioMérieux said on Tuesday that its first quarter 2021 revenues grew approximately 10 percent year over year. The firm also lowered its full-year sales guidance due to uncertainties in the business environment.

Danaher reported on Thursday a 58 percent year over year increase in total revenues driven by its Life Sciences revenues, which more than doubled.

Abbott announced before the market opened on Tuesday that its first quarter Diagnostics business revenues climbed 120 percent year over year.

Roche on Wednesday said its diagnostics sales during the first quarter 2021 grew 50 percent year over year, in part on demand for the company's COVID-19 products.

Autobio 's revenue was 2.978 billion yuan, while Liferiver reached was 2.052 billion yuan.

Recently, Beijing Strong Biotechnologies, Inc. successively reached strategic cooperation with Jilin Sinopharm and Liaoning Sinopharm; BEAVER completed the B round financing of tens of millions yuan; Demeter completed the A round of financin

In the first year of listing, Shenzhen New Industries Biomedical Engineering Co., Ltd. (Briefed as Snibe Co.,Ltd., Code No.: 300832. SZ) intends to repay shareholders well.

On April 15, 2021, the Wall Street Journal reported that Thermo Fisher, an American medical device giant would acquire PPD, a world-renowned CRO company for $17.4 billion.

Find out what is going on in Chinese in vitro diagnostic industry.

On April 16, 2021, GEM Listing Committee announced that the IPO registration application of ACROBiosystems was approved.